


FORM PTO 1449 (REV 2-32)		U.S.DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		File No. 97-28C1		Serial No. 09/852,472							
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)				Applicant(s): Paul O. Sheppard, Laura J. Jelinek									
				Filing Date: May 10, 2001		Group: 1646							
<b>U.S. PATENT DOCUMENTS</b>													
EXAMINER INITIAL		DOCUMENT NUMBER		DATE		NAME		CLASS		SUBCLASS		FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENTS</b>													
EXAMINER INITIAL		DOCUMENT NUMBER		DATE		COUNTRY		CLASS		SUBCLASS		FILING DATE IF APPROPRIATE	
		A1		97/01571		1/16/97							
		A2		93/12141		6/24/93							
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, Etc.)</b>													
MPP		A3	Marra et al., The Wash U-HHMI EST Project, Accession No. AA107358, 11/6/96.										
↑		A4	Marra et al., The Wash U-HHMI EST Project, Accession No. W12381, 4/29/96.										
		A5	Derwent Publications Ltd, Abstract No. 298110 '271 Of WO 97 19172, 5/29/97										
		A6	Joutel, et al., Nature 383:707-710, 1996.										
		A7	Lardelli, et al., Mechanisms of Development 46:123-136, 1994.										
		A8	Weinmaster et al., Development, 116:931-941, 1992.										
		A9	Katsanis et al., Trends in Genetics, 12(No.9):344, September, 1996.										
		A10	Li, et al., Molecular Biotechnology, University of Washington, Database EMBL, Accession No. U89335, 2/17/97.										
		A11	Sugaya, et al., Genomics 23:408-419, 1994.										
		A12	Robey, et al., Immunology Today 18( No. 2):55, 1997.										
		A13	Robey, et al., Cell 87:483-492, 1996.										
		A14	Lindsell, et al., Molecular and Cellular Neurosciences 8(No. 1):14-27, 1996.										
		A15	Robey, E., Current Opinion In Genetics & Development 7(No. 4):551-557, 1997.										
MPP		A16	Published EST 999399, 4/21/97.										
Examiner  MICHAEL PAUL								Date considered  1-20-03					
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.													

FORM PTO 1449  
(REV 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 97-28C1

Serial No.  
09/852,472SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Use several sheets if necessary)

Applicant(s):  
Paul O. Sheppard, Laura J. JelinekFiling Date:  
May 10, 2001

Group: 1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, Etc.)

mbp	A17	EST from Incyte Pharmaceuticals, Inc., 2953533, 4/1/97.
↑	A18	EST from Incyte Pharmaceuticals, Inc., 2794954, 4/1/97.
	A19	EST 914514, 3/28/97.
	A20	EST 890913, 3/12/97.
	A21	EST from Incyte Pharmaceuticals, Inc., 2572573, 3/10/97.
	A22	EST from Incyte Pharmaceuticals, Inc., 2569332, 3/10/97.
	A23	EST from Incyte Pharmaceuticals, Inc., 2569254, 3/10/97.
	A24	EST from Incyte Pharmaceuticals, Inc., 2740208, 3/10/97.
	A25	EST from Incyte Pharmaceuticals, Inc., 2742990, 3/10/97.
	A26	EST from Incyte Pharmaceuticals, Inc., LIN 1890253T6, 2/28/97.
	A27	Published EST LIN1890253F6, 2/28/97.
	A28	EST from Incyte Pharmaceuticals, Inc., 2734210, 2/4/97.
↓	A29	EST from Incyte Pharmaceuticals, Inc., 2596988, 2/4/97.
mbp	A30	EST from Incyte Pharmaceuticals, Inc., 2602924, 2/4/97.

Examiner

MICHAEL PM

Date considered

1/20/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449  
(REV 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Fil No. 97-28C1

Serial No.  
09/852,472SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTApplicant(s):  
Paul O. Sheppard, Laura J. JelinekFiling Date:  
May 10, 2001

Group: 1646

Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, Etc.)

MWP	A31	EST from Incyte Pharmaceuticals, Inc., 2515732, 2/4/97.
↑	A32	EST from Incyte Pharmaceuticals, Inc., 2477412, 2/4/97.
	A33	EST from Incyte Pharmaceuticals, Inc., 2599937, 2/4/97.
	A34	EST from Incyte Pharmaceuticals, Inc., 2235131, 1/22/97.
	A35	EST from Incyte Pharmaceuticals, Inc., 2318754, 1/22/97.
	A36	EST from Incyte Pharmaceuticals, Inc., 2458044, 1/22/97.
	A37	EST from Incyte Pharmaceuticals, Inc., 2320258, 1/22/97.
	A38	EST from Incyte Pharmaceuticals, Inc., 2263334, 1/22/97.
	A39	EST from Incyte Pharmaceuticals, Inc., 2469360, 12/9/96.
	A40	EST from Incyte Pharmaceuticals, Inc., 2156423, 12/9/96.
	A41	EST from Incyte Pharmaceuticals, Inc., 2254804, 12/9/96.
	A42	EST from Incyte Pharmaceuticals, Inc., 2357593, 12/9/96.
	↓	A43
MWP	A44	EST from Incyte Pharmaceuticals, Inc., 2192930, 11/5/96.

Examiner

Michael Park

Date considered

1/20/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449  
(REV 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 97-28C1

Serial No.  
09/852,472SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTApplicant(s):  
Paul O. Sheppard, Laura J. Jelinek

(Use several sheets if necessary)

Filing Date:  
May 10, 2001

Group: 1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, Etc.)

MOP	A45		EST from Incyte Pharmaceuticals, Inc., 2116417, 11/5/96.
↑	A46		EST from Incyte Pharmaceuticals, Inc., 2219320, 11/5/96.
	A47		EST from Incyte Pharmaceuticals, Inc., 2219509, 11/5/96.
	A48		EST from Incyte Pharmaceuticals, Inc., 2069246, 11/5/96.
	A49		EST from Incyte Pharmaceuticals, Inc., 2225677, 11/5/96.
	A50		EST from Incyte Pharmaceuticals, Inc., 2207851, 11/5/96.
	A51		EST from Incyte Pharmaceuticals, Inc., 2006037, 11/5/96.
	A52		EST 744973, 10/30/96.
	A53		EST from Incyte Pharmaceuticals, Inc., 2059470, 10/17/96.
	A54		EST from Incyte Pharmaceuticals, Inc., 1888138, 10/17/96.
	A55		EST from Incyte Pharmaceuticals, Inc., 1901474, 10/17/96.
	A56		EST from Incyte Pharmaceuticals, Inc., 1919526, 10/17/96.
↓	A57		EST from Incyte Pharmaceuticals, Inc., 2057046, 10/17/96.
MOP	A58		EST from Incyte Pharmaceuticals, Inc., 1873794, 10/17/96.

Examiner

MICHAEL DMK

Date considered

1/28/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449  
(REV 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 97-28C1

Serial No.  
09/852,472SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTApplicant(s):  
Paul O. Sheppard, Laura J. Jelinek

(Use several sheets if necessary)

Filing Date:  
May 10, 2001

Group: 1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, Etc.)

MDP	A59		EST from Incyte Pharmaceuticals, Inc., 1852058, 9/11/96.
↑	A60		EST from Incyte Pharmaceuticals, Inc., 1829985, 9/11/96.
	A61		EST from Incyte Pharmaceuticals, Inc., 1723234, 9/11/96.
	A62		EST 650474, 8/23/96.
	A63		EST 638278, 8/13/96.
	A64		EST from Incyte Pharmaceuticals, Inc., 1639832, 8/7/96.
	A65		EST from Incyte Pharmaceuticals, Inc., 1604802, 8/7/96.
	A66		EST from Incyte Pharmaceuticals, Inc., 1604854, 8/7/96.
	A67		EST from Incyte Pharmaceuticals, Inc., 1622844, 8/7/96.
	A68		EST from Incyte Pharmaceuticals, Inc., 1555968, 8/7/96.
	A69		EST from Incyte Pharmaceuticals, Inc., 1604768, 8/7/96.
	A70		EST from Incyte Pharmaceuticals, Inc., 1638747, 8/7/96.
↓	A71		EST 645746, 7/23/96.
MDP	A72		EST from Incyte Pharmaceuticals, Inc., 1415847, 7/15/96.

Examiner

MICHAEL PAH


Date considered

1/20/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449  
(REV 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 97-28C1

Serial No.  
09/852,472SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant(s):  
Paul O. Sheppard, Laura J. JelinekFiling Date:  
May 10, 2001

Group: 1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, Etc.)

MDP	A73	EST from Incyte Pharmaceuticals, Inc., 1361952, 7/15/96.
↑	A74	EST 584943, 6/20/96.
	A75	EST from Incyte Pharmaceuticals, Inc., 1317554, 6/18/96.
	A76	EST from Incyte Pharmaceuticals, Inc., 1358106, 6/18/96.
	A77	EST from Incyte Pharmaceuticals, Inc., 1323254, 6/18/96.
	A78	EST from Incyte Pharmaceuticals, Inc., 1356856, 6/18/96.
	A79	EST 575403, 6/14/96.
	A80	EST 575292, 6/14/96.
	A81	EST from Incyte Pharmaceuticals, Inc., 1367355, 5/20/96.
	A82	EST from Incyte Pharmaceuticals, Inc., 1373422, 5/20/96.
	A83	EST from Incyte Pharmaceuticals, Inc., 977730, 5/20/96.
	A84	EST from Incyte Pharmaceuticals, Inc., 1235528, 5/20/96.
↓	A85	EST from Incyte Pharmaceuticals, Inc., 1371141, 5/20/96.
MDP	A86	EST from Incyte Pharmaceuticals, Inc., 1210420, 5/20/96.

Examiner

MICHAEL PAU


Date considered

1/20/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449  
(REV 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 97-28C1

Serial No.  
09/852,472SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Use several sheets if necessary)

Applicant(s):  
Paul O. Sheppard, Laura J. JelinekFiling Date:  
May 10, 2001

Group: 1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, Etc.)

MDP	A87		EST from Incyte Pharmaceuticals, Inc., 1210893, 5/20/96.
↑	A88		EST 519439, 4/26/96.
	A89		EST from Incyte Pharmaceuticals, Inc., 990737, 4/23/96.
	A90		EST from Incyte Pharmaceuticals, Inc., 933048, 4/23/96.
	A91		EST 480825, 3/18/96.
	A92		EST 476175, 3/14/96.
	A93		EST from Incyte Pharmaceuticals, Inc., 829443, 3/5/96.
	A94		EST from Incyte Pharmaceuticals, Inc., 783112, 3/5/96.
	A95		EST 462261, 2/22/96.
	A96		EST from Incyte Pharmaceuticals, Inc., 747258, 2/2/96.
	A97		EST 431697, 1/5/96.
	A98		EST from Incyte Pharmaceuticals, Inc., 726194, 1/4/96.
↓	A99		EST from Incyte Pharmaceuticals, Inc., 687722, 1/4/96.
MDP	A100		EST from Incyte Pharmaceuticals, Inc., 693704, 1/4/96.

Examiner

MICHAEL PAK

Date considered

1/20/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449  
(REV 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 97-28C1

Serial No.  
09/852,472SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTApplicant(s):  
Paul O. Sheppard, Laura J. Jelin k

(Use several sheets if necessary)

Filing Date:  
May 10, 2001

Group: 1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, Etc.)

MDP ↑	A101	EST from Incyte Pharmaceuticals, Inc., 621775, 12/4/95.
	A102	EST from Incyte Pharmaceuticals, Inc., 607337, 12/4/95.
	A103	EST from Incyte Pharmaceuticals, Inc., 599782, 12/4/95.
	A104	EST from Incyte Pharmaceuticals, Inc., 601217, 12/4/95.
	A105	EST from Incyte Pharmaceuticals, Inc., 588150, 11/8/95.
	A106	EST 373949, 10/26/95.
	A107	EST from Incyte Pharmaceuticals, Inc., 486005, 10/6/95.
	A108	EST from Incyte Pharmaceuticals, Inc., 481470, 10/6/96.
	A109	EST from Incyte Pharmaceuticals, Inc., 371067, 8/25/95.
	A110	EST from Incyte Pharmaceuticals, Inc., 209532, 8/25/95.
	A111	EST from Incyte Pharmaceuticals, Inc., 208645, 8/25/95.
	A112	EST from Incyte Pharmaceuticals, Inc., 276889, 6/29/95.
	A113	EST 260834, 6/19/95.
MDP ↓	A114	EST 251174, 6/5/95.

Examiner

MICHAEL PAU

Date considered

1/20/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



[illegible]